Brief: Prothena Provides Updates On Portfolio Programs

Prothena

08/01/2024 17:44

Jan 8 (Reuters) - Prothena Corporation PLC  PRTA.O :
    * PROTHENA PROVIDES UPDATES ON PRX012, PRX123, BIRTAMIMAB
AND
PORTFOLIO PROGRAMS
    * PROTHENA CORPORATION PLC - REMAINS WELL FINANCED WITH
CASH, CASH
EQUIVALENTS, AND RESTRICTED CASH OF APPROXIMATELY $621 MILLION
AT YEAR END 2023
    * PROTHENA CORPORATION PLC - CASH, CASH EQUIVALENTS, AND
RESTRICTED CASH PROVIDES SUFFICIENT CAPITAL BEYOND COMPLETION OF
ITS ONGOING CLINICAL TRIALS
    * PROTHENA CORPORATION PLC - REMAIN ON TRACK WITH PARTNERED
PROGRAMS WITH BRISTOL MYERS SQUIBB, ROCHE AND NOVO NORDISK

Source text for Eikon:  ID:nBw6y2VJga 
Further company coverage:  PRTA.O 

 ((Reuters.Briefs@thomsonreuters.com;))